Clarius vs ScreenPoint Transpara

ScreenPoint's Transpara supports cancer detection on 2D FFDM and 3D DBT mammograms, and breast screening services reading mammograms are its customers. openFDA lists eight Transpara decisions, the latest in August 2026. The company raised EUR 13.6M in April 2026.

The vendor says Transpara was the software in MASAI, a randomized mammography screening trial in Sweden. The 2026 Lancet interval-cancer analysis of MASAI, academic work from Lund University, reported sensitivity of 80.5% with AI support against 73.8% for standard double reading, at 98.5% specificity, across more than 105,000 women. The vendor separately claims a 29% cancer detection increase and a 44% workload reduction.

The vendor says Clarius Prostate AI returns TRUS and TAUS prostate volume, and openFDA holds it as K243853. That suits a urology practice. Prostate volume and breast cancer detection are different clinical tasks on different devices, so a urology practice and a breast screening service buy separately.